RA Capital Management

# Signal Note: RA Capital Initiates Major ASND Position RA Capital's $2.2B entry into Ascendis represents significant validation of the company's endocrinology pipeline, particularly lonapegsomatropin (TransCon Growth Hormone) for growth hormone deficiency, which is advancing toward potential label expansions and international approvals. The timing suggests conviction ahead of near-term data readouts or regulatory decisions; Ascendis has multiple shots on goal including pediatric indications and adult GHD that could materially expand the addressable market. For a specialist biotech investor with Kolchinsky's track record in rare disease, this ~10% stake signals belief in execution risk mitigation and commercial trajectory despite the stock's recent volatility.

# Signal Note: RA Capital Initiates $714M Position in Rhythm Pharmaceuticals RA Capital's substantial entry into RYTM signals conviction in imparipotide (IMCIVREE) franchise expansion beyond POMC deficiency obesity—the lead indication that achieved FDA approval in 2020. The ~$714M position (6.67M shares) timing likely reflects confidence in upcoming clinical readouts or label expansion catalysts, given RA's typical thesis-driven investment horizon and Kolchinsky's track record backing rare genetic disorder monetization.

# Signal Note: RA Capital Initiates $623M Position in Avidity Biosciences RA Capital's substantial entry into RNA signals conviction in Avidity's RNA-targeting muscle disease pipeline, particularly its lead candidate AOC 1001 for myotonic dystrophy type 1 (DM1), which showed meaningful clinical benefit in Phase 1/2 data. The $623M stake (8.6M shares) represents a significant allocation and suggests confidence in near-term catalysts, likely including Phase 2 DM1 data readout and potential label expansion into other muscular dystrophies where RNA-targeting mechanisms remain underpenetrated.

# Signal Note: RA Capital Initiates $495M Position in Vaxcyte RA Capital's substantial entry into PCVX signals conviction in Vaxcyte's multi-valent pneumococcal conjugate vaccine (VaxPneupra) ahead of potential regulatory decisions; the program targets the large adult pneumococcal immunization market where it could compete against Pneumovax 23 and newer competitors like Merck's Pneumovax 20. The ~$495M stake (10.7M shares) suggests the firm views the risk/reward attractive relative to near-term catalysts, likely including FDA labeling or uptake trajectory as the vaccine gains formulary traction post-approval.

# Signal Note: RA Capital Initiates $407.5M Position in Sionna Therapeutics RA Capital's substantial entry into SION signals confidence in Sionna's pipeline, likely centered on its lead program targeting fibrotic diseases through selective autotaxin inhibition—a validated mechanism in IPF and other progressive fibroses. The $407.5M position size suggests conviction ahead of near-term clinical milestones, potentially Phase 2b readouts or partnership catalysts that could de-risk the platform's commercial potential in a multi-billion-dollar fibrosis market.

**Signal Note: RA Capital Initiates $342.7M Position in NewAmsterdam Pharma** RA Capital's $343M entry into NAMSW signals conviction in obicetrapib, NewAmsterdam's CETP inhibitor for cardiovascular risk reduction in statin-intolerant patients. The position timing likely reflects confidence ahead of Phase 3 readout expectations and potential regulatory pathway clarity, as CETP inhibitors have faced historical skepticism but recent apoB-lowering data may support differentiation. This represents meaningful validation from a top-tier biotech investor with strong track record in precision/cardiometabolic assets.

# Signal Note: RA Capital Initiates $321M Position in Tyra Biosciences RA Capital's substantial entry into TYRA signals conviction in the company's TYR-286 (selective TrkC inhibitor) pipeline, likely driven by upcoming Phase 2 data in neuropathic pain and potential label expansion beyond its current colorectal cancer indication. Kolchinsky's involvement suggests confidence in Tyra's mechanism and commercial opportunity, though near-term catalysts and clinical readouts will be critical to validate this thesis.

**Signal Note: RA Capital Initiates $309.5M Position in Wave Life Sciences** RA Capital's substantial new position suggests conviction in Wave's antisense pipeline, likely driven by upcoming data catalysts for WVE-120101 (SMA Type 1) and WVE-003 (DMD), both addressing large orphan markets with limited competition. The $309.5M stake (18.2M shares at ~$17/share) indicates confidence in near-term clinical readouts or regulatory progress, though Wave's historically volatile stock suggests the position reflects either significant de-risking events or bullish Phase 2/3 timing expectations.

# Signal Note: RA Capital Initiates $265.8M Position in Mineralys RA Capital's $265.8M entry into Mineralys (7.3M shares) signals conviction in the company's clinical-stage mineral metabolism portfolio, likely driven by upcoming catalysts in hyperphosphatemia and/or secondary hyperparathyroidism. Kolchinsky's track record backing early-stage biotech with defined regulatory pathways suggests confidence in a near-term data readout or FDA milestone that could de-risk valuation. This is a substantial first position rather than exploratory stake, indicating material probability weighting of clinical/commercial success.

**SIGNAL NOTE: RA Capital initiates $258.8M position in EWTX** RA Capital's entry into Edgewise signals conviction in EDG-5506 for muscular dystrophies, likely ahead of Phase 2b readout expected in DMD (Duchenne); the $259M stake (~10% of shares) suggests confidence in the selective myostatin inhibitor's differentiation versus competitors like Reata's eluforsen. Key catalysts include Phase 2b topline data (timing TBD) and potential label expansion across muscular dystrophy indications, though execution risk remains on efficacy and safety profile.

**Signal Note: RA Capital Initiates $195M Position in Septerna** RA Capital's entry into SEPN at scale signals confidence in Septerna's proprietary GPCR modulator platform, particularly for claudin-low breast cancer and other difficult-to-drug indications where the company's selective agonist approach may offer differentiation. Near-term value should track Phase 2 data readouts for lead candidates in claudin-low and potentially other oncology indications, alongside proof-of-concept in non-oncology applications (autoimmune/inflammatory). Given RA's expertise in precision biotech, the thesis likely hinges on target validation and clinical differentiation rather than near-term commercial potential.

**SIGNAL NOTE: RA Capital initiates $189M position in Nuvalent (NUVL)** RA Capital's entry into NUVL signals conviction in the company's pipeline of ALK/ROS1 inhibitors for non-small cell lung cancer, likely driven by near-term catalysts around clinical data readouts or regulatory milestones for lead candidates NVL-520 and NVL-655. This move by Kolchinsky's firm—known for early-stage biotech conviction—suggests confidence in NUVL's competitive positioning in the kinase inhibitor space, though execution risk remains material given the crowded ALK/ROS1 landscape.

**Signal Note: RA Capital initiates $157M position in IRON** RA Capital's entry into Disc Medicine signals conviction in their lead candidate DISC-0974, an oral MISTRG agonist in Phase 2 for myelodysplastic syndromes (MDS) and other blood disorders with unmet transfusion needs. The $156.9M stake (9.4% ownership) at a ~$1.67B implied valuation suggests confidence in near-term catalysts, likely Phase 2 efficacy readouts expected in 2025 for MDS and potentially other indications.

# Signal Note: RA Capital Initiates $154M Position in JANX RA Capital's $154M entry into Janux signals confidence in the company's bispecific platform, particularly JTX-4014 (CD4/CD25 bispecific) for autoimmune diseases where it has demonstrated clinical differentiation versus monotherapy approaches. The position sizing suggests conviction around near-term catalysts, likely including upcoming Phase 2 data readouts in lupus nephritis and other autoimmune indications expected through 2024-2025. Given Kolchinsky's track record of early-stage conviction plays, this indicates institutional-grade validation of Janux's mechanism and clinical trajectory before broader market recognition.

**Signal Note: RA Capital Initiates $130.6M Position in PepGen** RA Capital's entry into PEPG (20M shares, ~7.4% stake) signals conviction in PepGen's muscle disease franchise, primarily driven by PG101 (a muscle-targeted AAV therapy for limb-girdle muscular dystrophy type 2D). The position timing likely reflects anticipated near-term catalysts, including ongoing Phase 2 data readouts and potential regulatory pathway discussions for a rare indication with limited treatment options. Kolchinsky's thesis typically favors companies with validated biology and clear clinical milestones, suggesting RA sees a de-risked platform with material upside from multiple indications in PepGen's pipeline.